← Back to Search

Survivors of early-onset colorectal cancer, with recurrent disease (Training Cohort) for Colorectal Cancer (ENCORE Trial)

N/A
Waitlist Available
Led By Ajay Goel, PhD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 120 months
Awards & highlights

ENCORE Trial Summary

Survivors of early-onset colorectal cancer (diagnosed before age 50) may experience colorectal cancer recurrence several years after curative-intent treatments, but clinical guidelines provide unclear guidance on endoscopic surveillance. This study aims to predict recurrence-free survival and overall survival, in survivors of early-onset colorectal cancer, using a tumor-based molecular assay based on microRNA (ribonucleic acid)

Eligible Conditions
  • Colorectal Cancer

ENCORE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 120 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 120 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrence Free Survival
Secondary outcome measures
Overall Survival

ENCORE Trial Design

4Treatment groups
Experimental Treatment
Group I: Survivors of early-onset colorectal cancer, with recurrent disease (Validation Cohort)Experimental Treatment1 Intervention
Survivors of early-onset colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort
Group II: Survivors of early-onset colorectal cancer, with recurrent disease (Training Cohort)Experimental Treatment1 Intervention
Survivors of early-onset colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the first cohort
Group III: Survivors of early-onset colorectal cancer, with no recurrent disease (Validation Cohort)Experimental Treatment1 Intervention
Survivors of early-onset colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort
Group IV: Survivors of early-onset colorectal cancer, with no recurrent disease (Training Cohort)Experimental Treatment1 Intervention
Survivors of early-onset colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the first cohort

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
570 Previous Clinical Trials
1,922,439 Total Patients Enrolled
IRCCS San Raffaele Hospital, Milan, ItalyUNKNOWN
2 Previous Clinical Trials
10,683 Total Patients Enrolled
Institute of Biomedical Research of Salamanca, Salamanca, SpainUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
GutJournal
British Society of Gastroenterology/association of Coloproctology of Great Britain and Ireland/public Health England Post-polypectomy and Post-colorectal Cancer Resection Surveillance Guidelines
Rutter, Matthew D, James East, Colin J Rees, Neil Cripps, James Docherty, Sunil Dolwani, Philip V Kaye, et al.. 2019. “British Society of Gastroenterology/association of Coloproctology of Great Britain and Ireland/public Health England Post-polypectomy and Post-colorectal Cancer Resection Surveillance Guidelines”. Gut. BMJ. doi:10.1136/gutjnl-2019-319858.
clinicaltrials.govStudy
Early-Onset Colorectal Cancer Recurrence
2023. "Early-Onset Colorectal Cancer Recurrence". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06271980.
~85 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top